---
document_datetime: 2025-05-23 16:12:19
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zoledronic-acid-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7676728
conversion_datetime: 2025-12-23 05:58:53.250126
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zoledronic Acid Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - | 02/05/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000267263                      | Update of the package leaflet to introduce a list of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |             |                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000226953 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted To align the RMP for Zoledronic Acid Accord with the RMP of the reference product. In addition for the nationally authorised products Zoledronic Acid Accord 4 mg/5 ml, 4 mg/100 ml concentrate for solution for infusion (product reference PT/H/0742/001/DC) the RMP is being merged with the RMP of the centrally | 13/03/2025 | N/A |             | To align the RMP for Zoledronic Acid Accord with the RMP of the reference product. In addition for the nationally authorised products Zoledronic Acid Accord 4 mg/5 ml, 4 mg/100 ml concentrate for solution for infusion (product reference PT/H/0742/001/DC) the RMP is being merged with the RMP of the centrally authorised product. |
| Variation type IB / EMA/VR/0000231938 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent                                                                                                                                                                                                                                                                                                                                                                                                                                        | 13/11/2024 |     | SmPC and PL |                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                        | authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Other variation - Accepted Update of section 4.8 of the SmPC to add the adverse reaction \"Tubulointerstitial nephritis\" with the frequency \"not known\", following the assessment and approval of the same changes in the reference product. The Package leaflet has been updated accordingly.                              |            |                   |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type IA_IN / | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.a Implementation of wording agreed by the competent authority - Refused | 30/09/2024 | EMA/VR/0000228564 |